Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AVENUE THERAPEUTICS, INC. shareholders approved Authorization of the issuance of shares of Common Stock underlying warrants in an amount equal to or in excess of 20% of outstanding Common Stock at the 2024-01-09 meeting.
- Outcome
- passed
- Meeting
- 2024-01-09
Exact text from the filing
Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AVENUE THERAPEUTICS, INC. shareholders approved Approval of an increase in the number of authorized shares of Common Stock from 75,000,000 to 200,000,000 at the 2024-01-09 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2024-01-09
Exact text from the filing
Effective January 9, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent (i) approving an increase in the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“ Common Stock ”), from 75,000,000 to 200,000,000 (the “ Authorized Share Increase ”) through the filing of an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware and (ii) authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying warrants issued by the Company pursuant to those previously disclosed inducement letter agreements, dated as of January 5, 2024, by and between the Company and the investors named on the signature pages thereto, in an amount equal to or in excess of 20% of the number of shares of Common Stock outstanding immedi
View on SEC.gov